Drug intelligence / Profile preview

QLG1080

Development stage: Phase 3
Lead developer: Qilu Pharmaceutical
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Unknown

Overview

QLG1080 is a novel small molecule antineoplastic drug under development by Qilu Pharmaceutical for the treatment of prostate cancer. Its precise mechanism of action has not been disclosed or remains undefined as of the latest updates. The drug is being investigated primarily for hormone-sensitive advanced prostate cancer and is currently in preclinical and early clinical development stages in China, with plans for phase 3 trials underway[1][2][3][4][10].

Other names: QLG 1080QLG1080QLG-1080

Beyond the preview

Go deeper on QLG1080.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLG1080.

Explore the full profile